YS-H and KH prepared the manuscript and figures. YS-H and ST performed
autopsy. TY, MK and TN performed molecular detection of the virus. YM
analyzed the CT images. KF and MN cared the patient and prepared
clinical data. KI designated this study.
References1 Caramaschi S, Kapp ME, Miller SE, et al. Histopathological
findings and clinicopathologic correlation in COVID-19: a systematic
review. Mod Pathol. 2021; 34: 1614-33.
2 Agostini ML, Andres EL, Sims AC, et al. Coronavirus
Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the
Viral Polymerase and the Proofreading Exoribonuclease. mBio.
2018; 9.
3 Cevik M, Kuppalli K, Kindrachuk J, Peiris M. Virology, transmission,
and pathogenesis of SARS-CoV-2. BMJ. 2020; 371: m3862.
4 Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 Days
in Patients with Severe Covid-19. N Engl J Med. 2020;383: 1827-37.
5 Group RC, Horby P, Lim WS, et al. Dexamethasone in Hospitalized
Patients with Covid-19. N Engl J Med. 2021; 384:
693-704.
6 Gandhi RT. The Multidimensional Challenge of Treating COVID-19:
Remdesivir is a Foot in the Door. Clin Infect Dis. 2020.
7 Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of
Tocilizumab in Patients Hospitalized with Covid-19. N Engl J Med.
2020; 383: 2333-44.
8 Group RC. Tocilizumab in patients admitted to hospital with COVID-19
(RECOVERY): a randomised, controlled, open-label, platform trial.Lancet. 2021; 397: 1637-45.
9 Brown MJ, Alazawi W, Kanoni S. Interleukin-6 Receptor Antagonists in
Critically Ill Patients with Covid-19. N Engl J Med. 2021;385: 1147.
10 Gordon AC, Angus DC, Derde LPG. Interleukin-6 Receptor Antagonists in
Critically Ill Patients with Covid-19. Reply. N Engl J Med. 2021;385: 1147-49.
11 Schaller T, Hirschbuhl K, Burkhardt K, et al. Postmortem
Examination of Patients With COVID-19. JAMA. 2020; 323:
2518-20.
12 Yao XH, Luo T, Shi Y, et al. A cohort autopsy study defines
COVID-19 systemic pathogenesis. Cell Res. 2021; 31:
836-46.
13 Bryce C, Grimes Z, Pujadas E, et al. Pathophysiology of
SARS-CoV-2: the Mount Sinai COVID-19 autopsy experience. Mod
Pathol. 2021; 34: 1456-67.
14 Calabrese F, Pezzuto F, Fortarezza F, et al. Pulmonary
pathology and COVID-19: lessons from autopsy. The experience of European
Pulmonary Pathologists. Virchows Arch. 2020; 477:
359-72.
15 von Weyhern CH, Kaufmann I, Neff F, Kremer M. Early evidence of
pronounced brain involvement in fatal COVID-19 outcomes. Lancet.
2020; 395: e109.
16 Falasca L, Nardacci R, Colombo D, et al. Postmortem Findings
in Italian Patients With COVID-19: A Descriptive Full Autopsy Study of
Cases With and Without Comorbidities. J Infect Dis. 2020;222: 1807-15.
17 Adachi T, Chong JM, Nakajima N, et al. Clinicopathologic and
Immunohistochemical Findings from Autopsy of Patient with COVID-19,
Japan. Emerg Infect Dis. 2020; 26.
18 Okudela K, Hayashi H, Yoshimura Y, et al. A Japanese case of
COVID-19: An autopsy report. Pathol Int. 2020; 70:
820-24.
19 Keshinro SO, Awolola NA, Adebayo LA, Mutiu WB, Saka BA, Abdus-Salam
IA. Full autopsy in a confirmed COVID-19 patient in Lagos, Nigeria - A
case report. Hum Pathol (N Y). 2021; 24: 200524.
20 Update to living WHO guideline on drugs for covid-19. BMJ.
2021; 374: n2219.